To kick off Lung Cancer Awareness Month this November, the American Lung Association’s LUNG FORCE initiative, nationally presented by CVS Health, today announced its partnership with Grammy Award-winning singer Patti LaBelle to further educate the public about lung cancer, the leading cancer killer of women in the United States.
Personally affected by lung cancer, LaBelle hopes that lending her powerful voice to the cause will encourage all women to learn how they can make a difference in the fight to defeat lung cancer, which claims the life of one woman every eight minutes in the United States. Raising awareness is critical as only 1 percent of American women even have lung cancer on their health radar.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7664651-lung-force-patti-labelle-educate-public/
From a child development expert whose pet-centric curriculum is helping rehabilitate troubled adolescents to the founder of New York City’s first cat café, Purina’s third Better With Pets Summit showcased how the relationship between pets and people enhances overall emotional wellness.
The day-long summit, which was hosted by Emmy-nominated comedian and writer, Josh Gondelman, took place at the Brooklyn Expo Center in New York City on Nov. 3 and featured three panel discussions that examined the emotional relationship between pets and people, including the reciprocal effects both have on one another. Keynote speeches were presented by Purina senior research nutritionist Arleigh Reynolds, who has researched the dog and human bond for many years in Alaska and supports of The Frank Attla Youth Program; and author and reality television personality Carole Radziwill, who shared how pet ownership has shaped her life experiences.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7655851-purina-better-with-pets-summit/
Today, the award-winning Adoption from Foster Care campaign from the U.S. Department of Health and Human Services, AdoptUSKids and the Ad Council unveiled a new series of public service advertisements (PSAs) that aim to encourage the adoption of older youth from foster care.
Of the 415,000 children in the U.S. foster care system, 108,000 children under the age of 18 are currently waiting for adoptive families, according to the Adoption and Foster Care Analysis and Reporting System (AFCARS). Since the AdoptUSKids project began in 2002, 25,000 children who were once photo listed on adoptuskids.org are now with their adoptive families and nearly 38,000 families have registered to adopt through AdoptUSKids. 41 percent of the approximately 5,360 youth listed on the website are aged between 15 and 18 years old.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7673451-ad-council-national-adoption-campaign/
The nation’s largest provider of senior living solutions is offering tips for those who are concerned about showing signs of memory loss. These guidelines come along with Alzheimer’s Awareness month, celebrated each year in November.
“Here at Brookdale, we have a simple formula for people who may be worried about memory loss as it relates to Alzheimer’s and dementia, whether for themselves or for a loved one,” said Kelly Scott Lindstrom, Vice President of Dementia Care for Brookdale.
According to Lindstrom, three steps can help a person prepare for a potential Alzheimer’s diagnosis.
First, know the signs of Alzheimer’s disease. There are 10 common signs, and just because an individual may exhibit a couple of them doesn’t mean he or she has developed dementia.
Next, talk with your doctor, and he or she can help decipher a potential diagnosis of Alzheimer’s or if it is something unrelated.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7646052-brookdale-senior-living-alzheimer-s-facts/
The largest candy-consumption night of the year is right around the corner. More than 80 percent of parents say their kids will participate in a Halloween celebration (2), and when asked about concerns related to Halloween, more than two-thirds of parents say they are worried about their children’s teeth, according to a recent Ad Council survey (1). However, three out of four parents report that their kids sometimes or frequently forget to brush their teeth on a daily basis. With cavities being a top concern, the Kids’ Healthy Mouths campaign is celebrating National Brush Day® on Sunday, November 1, the day after Halloween, to emphasize the importance of brushing for two minutes, twice a day, every day.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7676151-kids-healthy-mouths-ad-council-brush-day/
(1), (2) The Ad Council’s survey was conducted by LightSpeed Research in September 2014. The nationally representative online survey included 600 parents with children 0-12.
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Pivotal Corporation, the Seattle start-up responsible for disrupting the wearable fitness marketplace with its $12 Pivotal Living Band, is pleased to announce pre-order availability for the Pivotal Living Smart Scale, a smarter scale with an even smarter price. Available for $39.95, just a fraction of the cost of most smart scales on the market, the elegant and efficient smart scale integrates seamlessly with the Pivotal Living app to provide a more intelligent way to manage body weight and overall health.
“Our mission has always been to spark a movement toward proactive health and wellness through affordable and powerful, personal health technology,” said David Donovick, CEO for Pivotal Corporation. “We are very proud to introduce a feature-rich smart scale to our family of products and software, and are thrilled to be able to offer it to our members at a pizza-dinner price!”
Using advanced bioimpedance technology, the Pivotal Living Smart Scale accurately measures key body weight and body fat percentage factors, helping people lose weight and stay healthy. Designed to help users identify when they are burning fat, building muscle and losing weight, the sleek smart scale displays weight on the scale’s easy-to-read LCD display screen and, when synced to the Pivotal Living mobile app, sends additional weight and body details. The scale’s four load sensors accurately assess body composition measurements based on weight and height data stored within the app. Working together, the scale and app measure and track.
To view the multimedia release go to:
http://www.multivu.com/players/English/7668051-pivotal-living-bluetooth-smart-scale/
Imagine being diagnosed with one of the most rare and aggressive forms of breast cancer, given a five percent chance to live and told having children will never be an option. Southern California local Kommah McDowell was told just that— and then she went to City of Hope.
It is estimated that almost 40 percent of men and women in the U.S. will be diagnosed with cancer sometime during their lifetime. Kommah, who was diagnosed at age 29, now has her health and her son, thanks to discoveries made at City of Hope, where scientists and doctors turn laboratory breakthroughs into treatments that defeat cancer.
Today, the nonprofit research and comprehensive cancer center near Los Angeles is rolling out a new initiative that builds on its legacy of discovery to let people know that City of Hope not only offers a uniquely patient-centric, integrated approach to care, but also with the help of donors and volunteers, it is pursuing research that will change the future of medicine.
To view the multimedia release go to:
http://www.multivu.com/players/English/7665051-city-of-hope-miracle-science-soul-campaign/
Results from two national surveys of patients receiving chemotherapy and pharmacists, conducted by the Hematology/Oncology Pharmacy Association (HOPA) in collaboration with Eisai Inc.,* found that 83% of patients receiving chemotherapy who have experienced chemotherapy-induced nausea and vomiting (CINV) believe it is a side effect with which they must live. Results also showed that 95% of cancer patients surveyed believe that CINV has, at some point, had an impact on their daily lives. These national surveys are part of the Time to Talk CINV™ campaign, which aims to increase awareness among patients and caregivers about CINV prevention and the importance of speaking with their pharmacist and full healthcare team about this often preventable side effect.
“The survey results underscore the confusion patients who are undergoing chemotherapy have about CINV and the need for them to understand that there are ways to manage their symptoms so that they do not have to needlessly suffer with CINV,” said Scott Soefje, PharmD, MBA, BCOP, President, Hematology/Oncology Pharmacy Association (HOPA) and Director of Pharmacy at the University Medical Center Brackenridge in Austin, TX. “It is imperative that patients discuss CINV prevention early in treatment and with all members of the health care team, including pharmacists.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7560331-time-to-talk-cinv/
Global health service company Cigna today announced it is expanding access to its popular Coach by Cigna health and fitness mobile application to make it more broadly available to its clients and customers. Coach is now available on both Apple® iOS and Android™ mobile smart devices.
Currently a go-to health and fitness app for more than 350,000 users in 15 nations in nine languages, Coach by Cigna is now available at no charge in the App Store ℠ and Google Play™ stores for mobile devices that have either the Apple® iOS9 or the Android™ Lollipop operating system.
To view the multimedia release go to:
http://www.multivu.com/players/English/7448831-coach-by-cigna-fitness-app/
